toxylact: a02ax01 carbenoxolone
The first professional lActological database in the word
A02BX01 corresponds to carbenoxolone, a glycyrrhetinic acid derivative used mainly for peptic and oral mucosal ulceration; its mineralocorticoid‑like toxicity and uncertain lactation safety make it unsuitable for breastfeeding mothers in systemic form.
Pharmacology and clinical use
Carbenoxolone is a semi‑synthetic derivative of glycyrrhetinic acid obtained from licorice root and classified in ATC A02BX01 “other drugs for peptic ulcer and gastro‑oesophageal reflux disease (GORD).” It exerts anti‑inflammatory and mucosal protective effects, promoting healing of gastric, duodenal, esophageal and oral ulcers and mucositis. The drug is used orally (tablets 50–300 mg) and topically (e.g. 2% creams or gels) for gastrointestinal and oral mucosal disease, typically in 2–3 divided doses for several weeks.
Mechanistically, carbenoxolone modulates prostaglandin synthesis and mucosal mucus production, enhancing epithelial proliferation and differentiation and reducing acid‑related injury in the upper gastrointestinal tract. It also inhibits 11β‑hydroxysteroid dehydrogenase type 1 (HSD11B1), leading to altered local glucocorticoid metabolism and contributing to mineralocorticoid‑like effects and potential systemic toxicity. Beyond gastroenterology, carbenoxolone has been studied experimentally as a gap junction blocker in neurology and endocrinology, but these indications remain investigational and are not standard clinical uses.
Toxicology and adverse effects
The main toxicological concern with carbenoxolone is a mineralocorticoid‑like syndrome characterized by sodium and water retention and disturbance of potassium homeostasis, driven by its effects on steroid metabolism. Patients may develop edema, weight gain, elevated blood pressure and arrhythmias associated with potassium imbalance; routine monitoring of blood pressure, body weight and serum electrolytes (especially potassium) is essential during systemic therapy. These adverse effects are dose‑related and more frequent with prolonged administration or in patients with pre‑existing cardiac or renal disease and older adults.
Serious toxicity includes clinically significant hypertension, congestive heart failure, and severe electrolyte imbalance requiring discontinuation of therapy and supportive management, such as loop diuretics and standard treatment of potassium abnormalities. Topical formulations for oral mucosal lesions have a much lower systemic burden and are generally considered non‑toxic when used appropriately, although application directly to the nipple or areola should be avoided or followed by careful cleansing to prevent infant ingestion. Routine contraindications to systemic carbenoxolone include uncontrolled hypertension, decompensated heart failure, significant renal impairment and conditions where fluid retention is undesirable; extra caution is required in pregnancy due to insufficient safety data.
Pregnancy and lactation safety
During pregnancy, carbenoxolone is generally not recommended because robust human data on teratogenicity and fetal safety are lacking, and its capacity to disturb maternal fluid and electrolyte balance may adversely affect pregnancy. Regulatory pregnancy risk classification is not clearly established in all jurisdictions, and some sources describe the drug as best avoided unless potential benefits clearly outweigh the risks. Given the availability of safer and better‑studied gastroprotective agents, carbenoxolone should not be a first‑line option in pregnant patients.
For lactation, the molecule’s high molecular weight and moderate oral bioavailability might limit transfer and infant exposure, but its relatively low protein binding and unknown milk/plasma ratio create uncertainty regarding breast milk excretion. Theoretical risks for breastfed infants include electrolyte disturbances, edema, cardiac arrhythmias and central nervous system excitation due to steroid metabolism interference and possible dopaminergic effects. In systemic use, this toxicity profile justifies classifying carbenoxolone as poor‑choice or unacceptable during breastfeeding, with preference for safer alternatives or temporary cessation of breastfeeding if treatment cannot be avoided.
Topical carbenoxolone applied to the oral mucosa or skin is considered low risk with minimal systemic absorption, but precaution is advised to avoid direct infant exposure by not applying on the breast and by cleaning treated areas thoroughly before nursing. Some lactation databases categorize carbenoxolone sodium as compatible or low risk under certain conditions, yet they also recommend careful evaluation and follow‑up because of heterogeneous data and variability between formulations and doses. Taken together, systemic carbenoxolone in breastfeeding mothers should be discouraged, while topical use away from the breast may be acceptable with appropriate safeguards and clinical monitoring.
Practical recommendations for healthcare professionals
When considering carbenoxolone for peptic or oral ulcerative disease, clinicians should weigh its mucosal healing benefits against the risk of mineralocorticoid‑like toxicity, especially in patients with cardiovascular or renal comorbidities. Baseline and periodic assessment of blood pressure, body weight and serum electrolytes is recommended, and therapy should employ the lowest effective dose for the shortest feasible duration. In ambulatory practice, clear patient counselling about potential symptoms of fluid retention and cardiac arrhythmia (palpitations, dyspnea, peripheral edema, rapid weight gain) can facilitate early detection of toxicity.
For pregnant and lactating patients, alternative anti‑ulcer and mucosal protective drugs with more favorable safety profiles (e.g. sucralfate or certain proton pump inhibitors) are generally preferred over systemic carbenoxolone. If topical carbenoxolone is used for oral mucosal disease in a breastfeeding mother, application should be limited to mucosal surfaces away from the breast, and both mother and infant should be monitored for unexpected systemic effects. Documentation of individual risk assessment, dosing, and monitoring strategy is advisable, given the limited high‑quality data in lactation and the potential for clinically meaningful toxicity.
